Caris Life Sciences (CAI) has introduced a new multimodal, AI-driven molecular insight designed to help determine whether certain non-small cell lung cancer patients benefit from adding chemotherapy- or may actually be harmed by it.
Non-small cell lung cancer (NSCLC) is the most common form of lung cancer and a leading cause of cancer-related deaths. For patients whose tumors are driver-negative and express high levels of PD-L1 (=50%), physicians often choose between immunotherapy alone or a combination of immunotherapy and chemotherapy. While chemotherapy can improve outcomes for some, it may reduce survival for others, making treatment decisions challenging.
Caris' new AI-powered signature was developed using its large-scale clinico-genomic datasets and the company's CodeAI platform, which integrates whole exome sequencing (WES), whole transcriptome sequencing (WTS), and real-world clinical data. The model works in two phases: first, it stratifies patient into higher-versus standard-risk groups; second, it predicts which patients are likely to benefit from adding chemotherapy.
The goal is to reduce unnecessary chemotherapy exposure and guide more biologically informed treatment decisions for physicians and patients. The signature also provides prognostic information, reinforcing the need for personalized therapy strategies.
Caris President David Spetzler said the new NSCLC treatment immunotherapy signature represents "an important step forward in personalizing NSCLC treatment," noting that avoiding potentially harmful chemotherapy can be life-changing for patients. He added that whole exome and transcriptome sequencing can deliver clinically actionable insights that smaller gene panels cannot.
Caris previously received FDA approval in November 2024 for MI Cancer Seek, the first and only WES/WTS-based assay with companion diagnostic indications for solid tumors.
CAI has traded between a low of $16.28 and a high of $42.50. The stock is currently trading at $19.83, up 5.73%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.